Haleon (NYSE:HLN) Earns Hold Rating from HSBC

Haleon (NYSE:HLN)‘s stock had its “hold” rating restated by analysts at HSBC in a research note issued to investors on Wednesday, Marketbeat.com reports.

A number of other equities analysts have also commented on the company. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Five analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.95.

Haleon Stock Performance

NYSE HLN opened at $10.39 on Wednesday. The firm has a market cap of $47.02 billion, a price-to-earnings ratio of 30.55, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average price of $9.65 and a 200-day moving average price of $9.85. Haleon has a twelve month low of $7.89 and a twelve month high of $10.80.

Haleon (NYSE:HLN) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. As a group, equities research analysts predict that Haleon will post 0.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Haleon

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HLN. Sierra Ocean LLC purchased a new stake in Haleon during the fourth quarter valued at approximately $26,000. Versant Capital Management Inc raised its holdings in shares of Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after buying an additional 3,348 shares during the period. Geneos Wealth Management Inc. purchased a new stake in shares of Haleon in the fourth quarter worth approximately $35,000. Toronto Dominion Bank raised its holdings in shares of Haleon by 3,470.0% in the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after buying an additional 3,470 shares during the period. Finally, Spire Wealth Management purchased a new stake in shares of Haleon in the fourth quarter worth approximately $39,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.